LU91854I2 - Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®) - Google Patents

Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)

Info

Publication number
LU91854I2
LU91854I2 LU91854C LU91854C LU91854I2 LU 91854 I2 LU91854 I2 LU 91854I2 LU 91854 C LU91854 C LU 91854C LU 91854 C LU91854 C LU 91854C LU 91854 I2 LU91854 I2 LU 91854I2
Authority
LU
Luxembourg
Prior art keywords
halaven
eribulin
pharmaceutically acceptable
acceptable derivatives
useful
Prior art date
Application number
LU91854C
Other languages
English (en)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91854(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of LU91854I2 publication Critical patent/LU91854I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
LU91854C 1998-06-17 2011-08-17 Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®) LU91854I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (fr) 1998-06-17 1999-06-16 Analogues macrocycliques, leurs procedes d'utilisation et de preparation

Publications (1)

Publication Number Publication Date
LU91854I2 true LU91854I2 (fr) 2011-10-17

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91854C LU91854I2 (fr) 1998-06-17 2011-08-17 Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)

Country Status (23)

Country Link
US (4) US6214865B1 (fr)
EP (4) EP2272840B1 (fr)
JP (1) JP4454151B2 (fr)
KR (1) KR100798600B1 (fr)
CN (1) CN1216051C (fr)
AT (1) ATE502932T1 (fr)
AU (1) AU762998B2 (fr)
BE (1) BE2011C028I2 (fr)
BR (1) BRPI9911326B8 (fr)
CA (3) CA2755266C (fr)
CY (2) CY1111516T1 (fr)
DE (2) DE122011100031I1 (fr)
DK (1) DK1087960T3 (fr)
FR (1) FR11C0038I2 (fr)
HK (1) HK1035534A1 (fr)
HU (1) HU227912B1 (fr)
IL (1) IL139960A0 (fr)
LU (1) LU91854I2 (fr)
NO (5) NO328280B1 (fr)
NZ (1) NZ508597A (fr)
PT (1) PT1087960E (fr)
WO (1) WO1999065894A1 (fr)
ZA (1) ZA200007159B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (fr) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermédiaire pour la preparation d'analogues d'halichondrine
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
KR101208266B1 (ko) 2002-03-22 2012-12-05 에자이 알앤드디 매니지먼트 가부시키가이샤 헤미아스텔린 유도체 및 이의 용도
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
JP2007500240A (ja) * 2003-05-29 2007-01-11 アボット・ラボラトリーズ Ａｂｔ−７５１による持続投与レジメン
EP1653953A4 (fr) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd Procedes et dispositifs pour la delivrance de medicaments
PL2522663T3 (pl) * 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
CN104311571B (zh) * 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
SG189739A1 (en) * 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
RS55148B1 (sr) 2009-03-30 2016-12-30 Eisai R&D Man Co Ltd Smeša lipozoma
WO2010113983A1 (fr) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de mise au point d'une composition liposomique
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
JP5556811B2 (ja) * 2009-04-14 2014-07-23 日産化学工業株式会社 テトラヒドロピラン化合物の製造方法
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
SG193489A1 (en) 2011-03-18 2013-10-30 Eisai R&D Man Co Ltd Methods and compositions for predicting response to eribulin
WO2012147900A1 (fr) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Procédé en microréacteurs pour synthèse d'analogue d'halichondrine b
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
AU2012363334B2 (en) * 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
US20140163095A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
TW201514159A (zh) 2013-05-15 2015-04-16 Alphora Res Inc ３-（（２ｓ，５ｓ）-４-亞甲基-５-（３-氧代丙基）四氫呋喃-２-基）丙醇衍生物、其製備及對其有用的中間體
CA2915005C (fr) 2013-06-26 2021-12-28 Eisai R&D Management Co., Ltd. Utilisation d'eribuline et de lenvatinib en tant que polytherapie pour le traitement du cancer
EP3016957A4 (fr) * 2013-07-03 2016-11-30 Alphora Res Inc Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans la synthèse, notamment des intermédiaires contenant des groupes -so2-(p-tolyle)
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
JP6443812B2 (ja) 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類縁体の合成に有用な方法
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
EP3148526B1 (fr) * 2014-05-28 2021-01-06 Eisai R&D Management Co., Ltd. Utilisation de l'éribuline dans le traitement du cancer
EP3160970A4 (fr) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthèse d'analogues d'halochondrines et leurs utilisations
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
MX2017010474A (es) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Metodo para suprimir el amargor de un derivado de quinoleina.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201706872SA (en) * 2015-03-04 2017-09-28 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
WO2016179607A1 (fr) * 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Réactions de macrocyclisation et intermédiaires et autres fragments utiles dans la synthèse de macrolides halichondrine
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
EP3413887B1 (fr) 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermédiaires utilisés dans la synthèse d'éribuline et procédés de synthèse associés
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2017203459A1 (fr) 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Procédé de préparation d'éribuline et de ses intermédiaires
CN109641917B (zh) 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
AU2017342462A1 (en) 2016-10-14 2019-05-02 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
KR20190084065A (ko) 2016-11-23 2019-07-15 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그 중간체의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
WO2018124847A1 (fr) 2017-01-02 2018-07-05 연성정밀화학(주) Intermédiaire de production de mésylate d'éribuline, et son procédé de production
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
PT3606928T (pt) 2017-04-05 2022-12-05 Harvard College Composto macrocíclico e utilizações deste
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
JP6967811B2 (ja) * 2017-11-09 2021-11-17 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
EP4403560A2 (fr) 2017-11-15 2024-07-24 President And Fellows Of Harvard College Composés macrocycliques et utilisations de ceux-ci
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (fr) 2017-11-21 2019-05-31 Natco Pharma Limited Préparation d'intermédiaires d'éribuline
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of helicondrin macrolides and their analogs
WO2019211877A1 (fr) 2018-05-03 2019-11-07 Cipla Limited Procédé de préparation d'analogues cétoniques macrocycliques de halichondrine b
WO2020008382A1 (fr) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Procédé de préparation d'éribuline et de ses intermédiaires
WO2020016847A2 (fr) * 2018-07-20 2020-01-23 Dr. Reddy’S Laboratories Limited Procédé de purification pour la préparation d'éribuline et de ses intermédiaires
WO2020075027A1 (fr) * 2018-10-09 2020-04-16 Dr. Reddy's Laboratories Limited Procédé de préparation d'éribuline et de ses intermédiaires
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US20220333139A1 (en) 2019-06-21 2022-10-20 Council Of Scientific And Industrial Research A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
PE20230467A1 (es) 2019-11-07 2023-03-14 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
CA3168654A1 (fr) * 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Conjugue de medicament a base de derive d'eribuline, son procede de preparation et son application en medecine
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
WO2023212746A2 (fr) * 2022-04-30 2023-11-02 William Marsh Rice University Stratégie unifiée pour la synthèse totale d'un analogue d'éribuline et de macrolactame d'halichondrine b
CN118356507A (zh) * 2023-01-17 2024-07-19 成都百利多特生物药业有限责任公司 一种艾日布林类药物的偶联物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (fr) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermédiaire pour la preparation d'analogues d'halichondrine
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN104311571B (zh) * 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
CA2705383A1 (fr) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Nouveau produit intermediaire pour la synthese de l'analogue de l'halichondrine b et nouvelle reaction de desulfonylation utilisee pour le produit intermediaire
SG189739A1 (en) * 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
JP5800834B2 (ja) * 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体

Also Published As

Publication number Publication date
NO331183B1 (no) 2011-10-24
CN1312804A (zh) 2001-09-12
BR9911326B1 (pt) 2015-01-06
KR20010083050A (ko) 2001-08-31
BRPI9911326B8 (pt) 2021-05-25
DE122011100031I1 (de) 2011-12-15
CA2632433C (fr) 2012-02-07
WO1999065894A1 (fr) 1999-12-23
BR9911326A (pt) 2001-04-03
KR100798600B1 (ko) 2008-01-28
CA2755266A1 (fr) 1999-12-23
CA2632433A1 (fr) 1999-12-23
US6469182B1 (en) 2002-10-22
JP4454151B2 (ja) 2010-04-21
AU762998B2 (en) 2003-07-10
IL139960A0 (en) 2002-02-10
EP2272839B1 (fr) 2012-08-22
HK1035534A1 (en) 2001-11-30
EP2272840B1 (fr) 2012-08-22
RU2245335C2 (ru) 2005-01-27
NO2011026I1 (no) 2012-01-09
NO2011026I2 (no) 2012-06-11
CY2011010I2 (el) 2014-04-09
NO20006316L (no) 2001-02-15
CA2335300A1 (fr) 1999-12-23
BE2011C028I2 (en) 2018-08-24
DK1087960T3 (da) 2011-06-14
PT1087960E (pt) 2011-06-17
JP2002518384A (ja) 2002-06-25
CY2011010I1 (el) 2014-04-09
ZA200007159B (en) 2001-12-04
EP1087960A4 (fr) 2004-12-01
US8148554B2 (en) 2012-04-03
CY1111516T1 (el) 2014-04-09
AU4573999A (en) 2000-01-05
DE69943296D1 (de) 2011-05-05
NZ508597A (en) 2004-01-30
NO328280B1 (no) 2010-01-25
CA2335300C (fr) 2008-10-07
US20110172446A1 (en) 2011-07-14
US6214865B1 (en) 2001-04-10
HUP0103357A3 (en) 2002-10-28
AU762998C (en) 2000-01-05
CN1216051C (zh) 2005-08-24
EP2277873A1 (fr) 2011-01-26
NO2011018I1 (no) 2011-09-26
HU227912B1 (en) 2012-05-29
HUP0103357A2 (hu) 2002-01-28
ATE502932T1 (de) 2011-04-15
NO20006316D0 (no) 2000-12-12
EP2277873B1 (fr) 2012-05-30
FR11C0038I2 (fr) 2013-01-11
EP1087960A1 (fr) 2001-04-04
FR11C0038I1 (fr) 2011-10-14
EP2272839A1 (fr) 2011-01-12
CA2755266C (fr) 2014-08-12
NO20093217L (no) 2001-02-15
EP1087960B1 (fr) 2011-03-23
US6365759B1 (en) 2002-04-02
EP2272840A1 (fr) 2011-01-12
NO2022019I1 (no) 2022-06-03

Similar Documents

Publication Publication Date Title
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
AUPR213700A0 (en) Antiviral agents
MX9707453A (es) Derivados de quinazolina.
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
ATE181551T1 (de) Taxol-derivate
EA200100983A1 (ru) Производные 13-метилэритромицина
LU91178I2 (fr) Emtricitabine / Tenofovir Disoproxil et ses dérivés pharmaceutiquement acceptables (TRUVADA).
DE60005517D1 (de) Kaliumkanal-blockierende mittel
BR0014687A (pt) Compostos de taxano pentacìclico
RS50033B (sr) Derivati etansulfonil-piperidina
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
EA200200292A1 (ru) Производные гигромицина
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
KR970702869A (ko) 항종양성 인돌로피롤로카르바졸 유도체(antitumor indolopyprolocarbazole derivative)
BR9902049A (pt) Derivados 9a,11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina.
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων